MCKNIGHT BRAIN RESEARCH FOUNDATION (MBRF)

Meeting of the Finance Committee of the Board of Trustees

Tuesday, January 21, 2025 7:00 – 8:00 PM EST via TEAMS

Members:		Dr. Allison Brashear, Chair; Ms. Melanie Cianciotto, Corporate Trustee; Dr. Michael L. Dockery, MBRF Chair; and Dr. Sue Pekarske					
Also Attending:		Ms. Amy Porter					
		AGENDA					
7:00 pm EST	1.	Call to Order/Welcome/Roll Call	Dr. Brashear				
ACTION	2.	Review of Minutes from May 6, 2024	Dr. Brashear				
	3.	For Information Updated Finance Committee Activity Timeline	Dr. Brashear				
	4.	Annual Endowment Reports a. University of Arizona b. University of Miami	Dr. Brashear				
ACTION	5.	Review Financial Information in the MBI Annual Reports a. University of Alabama at Birmingham b. University of Arizona c. University of Florida d. University of Miami	Dr. Brashear Ms. Cianciotto				
	6.	 Next Steps/New/Old or Other Business a. SfN 2025 MBRF Poster Session b. 2025 Grantmakers in Aging Membership c. 2025 Evelyn F. McKnight Clinical Translational Research Scholars Dinner (AAN) 	Dr. Brashear Ms. Cianciotto				
8:00 pm EST	7.	Adjourn	Dr. Brashear				

ACTION

MINUTES MCKNIGHT BRAIN RESEARCH FOUNDATION Finance Committee Via TEAMS May 6, 2024

The Finance Committee of the MBRF TEAMS conference call was called to order at 5:05 p.m. EST on May 6, 2024 (See Agenda – Attachment 1)

The following members were present:

- Dr. Allison Brashear, Chairman
- Dr. Michael Dockery, MBRF Chair
- Dr. Sue Pekarske, Trustee
- Ms. Melanie Cianciotto, Corporate Trustee, Truist Foundations and Endowments Specialty Practice

Others attending:

Dr. Angelika Schlanger, Executive Director

1. Approval of Minutes

The minutes of the MBRF January 22, 2024, TEAMS Committee conference call (Attachment 2) were reviewed and approved as amended.

The changes were:

Top of the minutes: Change January 24, 2024 to January 22, 2024

Item 5: In the second paragraph, first sentence, change "this" to "which" after 25th anniversary,.

Action Item 1: The Finance Committee members approved the minutes of the January 22, 2024, Finance Committee TEAMS conference call as amended (Attachment 2).

2. Review of the Updated Finance Committee Activity Timeline

The Finance Committee reviewed the updated Finance Committee Activity Timeline (Attachment 3) for information.

Action Item 2: The Finance Committee members received the updated Finance Committee Activity Timeline (Attachment 3) for information.

3. <u>Trustee Compensation Discussion</u>

Ms. Cianciotto presented updated compensation information compiled from information obtained from Exponent Philanthropy and the Council on Foundations (Attachment 4). The current trustee compensation of \$40,000 is based on \$200 per hour. The trustees have previously agreed each spend, on average, a minimum of 4 to 8 hours per week on Foundation matters during a 50 week time period. The trustee compensation has not been changed since it was set in 2000. The committee proposes the trustee compensation be increased to either \$250 or \$300 per hour. The committee asked Ms. Cianciotto to reach out to the MBRF Legal Counsel, Rob Wall, and ask if this is reasonable and would it pass the IRS test. The committee also proposes the Chair be awarded a stipend of \$10,000 per year.

Action Items 3: Ms. Cianciotto will reach out to the MBRF Legal Counsel, Rob Wall, and ask if an increase of \$250 or \$300 per hour is reasonable and would it pass the IRS test.

4. MBRF Proposed Financials

The committee reviewed the MBRF Proposed Financials for 7/1/2024 – 6/30/2025 (Attachment 5). The committee requested a Scope of Work covering Ms. Patmintra's consulting fees for 7/1/2024 – 6/30/2025. The committee approved the MBRF Proposed Financials for 7/1/2024 – 6/30/2025 pending receipt of a Scope of Work from Ms. Patmintra.

Action Item 4: Ms. Cianciotto will ask Ms. Patmintra to provide a Scope of Work.

Action Item 5: The committee approved the MBRF Proposed Financials for 7/1/2024 – 6/30/2025 pending receipt of a Scope of Work from Ms. Patmintra.

5. Next Steps/New/Old Business

As a follow up to the meeting with the Leadership Council at the May 2023 Inter-Institutional Meeting, the MBRF has received a proposal to restructure the McKnight Brain Aging Registry (MBAR) and spend the remaining funds of \$88,000. The \$88,000 represents unspent funds from the three Cores that were approved many years ago. The funds have continued to be spent down and there is not \$88,000 available for the MBAR proposal. Dr. Dockery proposed letting MBAR spend down the remaining funds and approving the current proposal with new funds. A recommendation was made to approve funding the MBAR proposal de nove, not out of existing funds. The committee approved. Dr. Schlanger will let Dr. Visscher know that all outstanding invoices need to be

submitted by June 1st and then the Cores will be closed. The new funding for MBAR would begin July 1, 2024 and run for a period of two years.

Action Item 6: The committee approves funding the MBAR proposal de nove, not out of existing funds.

There being no further business, the meeting was adjourned at 6:00 p.m. EST.

Summary of Action Items:

Respectfully Submitted,

Melanie A. Cianciotto

Truist Bank, Corporate Trustee

melania Ciarciotto

Finance Committee Activity Timeline For the One-Year Period July 1, 2023, to June 30, 2024

Updated January 15, 2025

Duty	Activity/Action	Outcome	Date	Comments
(from Committee Charter)				
"shall coordinate the Board of Trustee's Financial Oversight	Review Investments and Investment Policy	Asset Allocation Review (Mike Hill)	August 22, 2024	completed
Responsibilities (through monitoring of)financial management, assets, and		Efficient Frontier Analysis (Shelly Simpson)	August 22, 2024	completed
risks"		Monte Carlo Simulation		upon recommendation by Truist or request of the MBRF
		Investment Performance Review	August 22, 2024	completed
		Investment Performance & Asset Allocation Review (Mike Hill)	October 14, 2024	completed
	·	Investment Performance & Asset Allocation Review (Mike Hill)	February 2025	
		Investment Performance & Asset Allocation Review (Mike Hill)	May 14, 2025	

Duty (from Committee Charter)	Activity/Action	Outcome	Date	Comments	
Financial Oversight "Ensure Compliance with Federal, State and other Financial Reporting Requirements"	Assess and Maintain IRS Required Distribution Amount	Minimum Distribution Calculation Report	August 22, 2024 October 14, 2024 February 2025 May 14, 2025	completed completed	
	Compensation Review	Examples Presented for Comparison	May 2025		
	Tax Filing	Legal Counsel for the MBRF reviews the completed tax form before filing		7/1/2022 - 6/30/2023 was filed on 5/14/2024	
	Insurance	MBRF carries D & O Insurance	Renewed annually	Premium paid by Corporate Trustee	
Financial Oversight " planning, monitoring and evaluation offunding for the McKnight Brain Institutes and the MBRF Operations"	Monitor Current and Outstanding Gifts and Grants	Gifts and Grants Report	August 22, 2024 October 14, 2024 February 2025 May 14, 2025	completed completed	
operation.		Travel Award Program Report	August 22, 2024 October 14, 2024 February 2025 May 14, 2025	completed completed	
	Review MBRF Operating Expenses	Year to Date Operating Expenses Report	August 22, 2024 October 14, 2024 February 2025 May 14, 2025	completed completed	
		Review & Approve Annual Operating Budget	May 14, 2025		

Duty (from Committee Charter)	Activity/Action	Outcome	Date	Comments
Financial Reviewof reports and requests submitted to the MBRF by the MBIs and Other Partners	Review Financial Reports Submitted with the MBI's Annual Reports		January 2025	
	Review Financial Information included in Interim and Final Reports for Research <u>Gra</u> nts		Per terms of the award letter	
	Review Budgets Submitted with Requests for Funding		As submitted	
"ensure adequacy of MBRF internal controls and compliance with conflict of interest policy	Review Signing Authority	MBRF policy is minimum of 2 individuals with signing authority	July 12, 2024	Completed Signers are good for 5 years unless there is a change in the signers for the account
	Conflict of Interest	Conflict of Interest Policy signed by all new and re-elected Trustees and by all Advisory Members of MBRF Committees	ONGOING	

Account Activity Report

E. F. McKnight Brain Institute Endowment

College of Science

Department of Psychology

Account Number 40-10-4500

Established 6/24/2014

Activity from July 1, 2023 to June 30, 2024

FUND PERFORMANCE

Beginning market value at 07/01/2023	\$10,467,549.49
Investment performance	801,843.74
Endowment payout	(445,464.90)
Endowment fee	(106,736.57)
New gifts and additions	262,839.55
Ending market value at 06/30/2024	\$10,980,031.31
Historical Gift Value at 06/30/2024	\$ 9,719,296.90
PROJECTED PAYOUT FY 2024-25*	\$ 463,747.92

*This amount may be wholly or partially capitalized into the fund as specified in the endowment agreement.

The Payout is the annual distribution from the endowment for the fund's purpose and is equal to 4.25% of the average fair value of the corpus of an endowment at the end of the 12 quarterly periods within the three previous calendar year-ends. The Historical Gift Value is the sum of all gifts received into an endowed fund since its creation. Additional information can be found on page 7 of the Annual and Endowment Report.

Questions? Please contact donorservices@uafoundation.org or 520-621-5491.



Account Activity Report

Evelyn F. McKnight Chair for Learning and Memory in Aging
Research, Innovation and Impact
Account Number 40-00-2093
Established 12/30/2010

Activity from July 1, 2023 to June 30, 2024

FUND PERFORMANCE

Beginning market value at 07/01/2023	\$ 933,967.18
Investment performance	69,882.97
Endowment payout	(39,124.44)
Endowment fee	(9,373.82)
New gifts and additions	0.00
Ending market value at 06/30/2024	\$ 955,351.89
Historical Gift Value at 06/30/2024	\$ 1,000,000.00
PROJECTED PAYOUT FY 2024-25*	\$ 40,349.88

^{*}This amount may be wholly or partially capitalized into the fund as specified in the endowment agreement.

The Payout is the annual distribution from the endowment for the fund's purpose and is equal to 4.25% of the average fair value of the corpus of an endowment at the end of the 12 quarterly periods within the three previous calendar year-ends. The Historical Gift Value is the sum of all gifts received into an endowed fund since its creation. Additional information can be found on page 7 of the Annual and Endowment Report.

Questions? Please contact donorservices@uafoundation.org or 520-621-5491.





November 15, 2024

Michael L. Dockery, M.D.
Madhav Thambisetty, MD; PhD
Patricia A. Boyle, Ph.D.
John E. Brady, MD
Sharon A. Brangman, MD
Allison Brashear, M.D., M.B.A
Roy H. Hamilton, MD.
Susan Pekarske, MD
J. Lee Dockery, M.D. Emeritus
Melanie Cianciotto, Corporate Trustee
Amy Porter., Interim Executive Director

Trustees, The Evelyn F. McKnight Brain Research Foundation, Inc. Truist Bank
Mail Code 886-73-17-50
333 S. Garland Avenue, 17th Floor,
Orlando, FL 32801

Dear Trustees:

On behalf of the University of Miami Leonard M. Miller School of Medicine, please find enclosed the growth pool annual investment report for the fiscal year ending May 31, 2024. Per the terms of our gift agreement (section 7.3) the University of Miami forwards this report to you annually. I have also included the market value analysis for the endowment for the same fiscal period.

Should you have any questions, please feel free to contact me or Susan Fox-Rosellini.

Thank you for your continued support and collaboration in our efforts.

Warmest regards,

Tatiana Dundel

TATJANA RUNDEK, MD, PhD

Professor of Neurology and Public Health Sciences

Evelyn F. McKnight Endowed Chair for Learning and Memory in Aging

Director, Evelyn McKnight Brain Institute

Executive Vice Chair of Research and Faculty Affairs in Neurology

Director, Clinical Translational Research Division in Neurology

Director, Master of Science Program in Clinical Translational Investigation

BME Graduate Faculty of College of Engineering

Enclosures

cc: Susan Fox-Rosellini,

University of Miami Evelyn F. McKnight Brain Institute's Endowments Summary Analysis at Market Value June 1, 2023 - May 31, 2024

2002 Gift & Match

	M	velyn F. IcKnight 880 (262080)	ENC	F.Peterson/ McKnight 001065 (262293)		Schoninger Professorship in Neurology 001211 (262453)		Schoninger Neuropsychology Clinic N001212 (262454)		Other sources		<u>Total</u>
Beginning Balance at Market, 6/1/23	\$	7,868,591	\$	1,217,346	\$	2,106,027	\$	2,763,385	\$	-	\$	13,955,349
Investment Return		1,314,297		203,337		351,771		461,578				2,330,983
Distributions for Spending		(338,201)		(52,323)		(90,520)		(118,774)				(599,818)
Transfers from other University funds												-
New gifts												-
Ending Balance at Market, 05/31/24	ć	8,844,687	ć	1,368,360	Ś	2,367,278	ć	3,106,189	Ś		ć	15,686,514

2014 Gift & Match							
	Pr Mem	choninger ofessor in ory Disorders 1227 (262471)	Evelyn F. McKnight ndowed Chair 01246 (262490)				<u>Total</u>
Beginning Balance at Market, 6/1/23	\$	2,263,540	\$ 2,495,152	\$ - 5	\$ -	\$ -	\$ 4,758,692
Investment Return		378,088	416,768				794,856
Distributions for Spending		(97,290)	(107,245)				(204,535)
Transfers from other University funds							-
Matching gifts							-
McKnight Foundation gifts							-
Ending Balance at Market, 05/31/24	\$	2,544,338	\$ 2,804,675	\$ - !	\$ -	\$ -	\$ 5,349,013

University of Miami Evelyn F. McKnight Brain Institute's Endowments at the Miller School of Medicine Market Value Analysis 05/31/2024


2002 Gift & Match	
McKnight Contribution	\$ 5,000,000
UM Match	5,050,913
Transfers from Other University Funds	1,362,153
New Gifts	1,000,025
Investment Return	12,014,549
Distributions for Spending	(8,741,126)
05/31/24 Endowment Balance	\$ 15,686,514
Unmatched Balance	\$ -
2014 Gift & Match	
McKnight Contribution	\$ 2,000,000
UM Match	2,000,000
Transfers from Other University Funds	-
Investment Return	2,887,090
Distributions for Spending	(1,538,077)
05/31/24 Endowment Balance	\$ 5,349,013
McKnight Foundation Pledge Balance	\$ -

University of Miami - All Managed Assets Performance Periods Ending: May 31, 2024

Total Returns (Periods Greater Than 1 Year are Annualized)									
Growth Pool	Inception	1 Year (%)	3 Year (%)	5 Year (%)	7 Year (%)	10 Year (%)			
Growth Pool Total Composite*	12/31/1990	17.68	4.65	9.42	8.02	6.77			
Growth Pool Market Benchmark**	12/31/1990	19.14	3.88	9.17	7.81	6.98			
Value (+/-)		-1.46	0.77	0.26	0.21	-0.20			

Inception-to-Date Growth Pool Risk/Return as of May	31, 2024	
Growth Pool	15 Year Return	15 Year Standard Deviation
Growth Pool Total Composite	8.51	9.91
Growth Pool Market Benchmark	8.76	10.98

^{*}Net of fee returns



^{**} A weighted average return derived by applying the target policy weights of each asset class to the performance of the asset class benchmarks

UNIVERSITY OF MIAMI - GROWTH POOL


Manager Structure - Market Values and Allocations Period Ending May 31, 2023

Asset Class Market Value (5) % of Total Fund Large/Mid/All Cap Equity 39.2%		Growth Pool		
LargeMid/All Cap Equity	Manager		Market Value (\$)	% of Total Fund
Vanguard Institutional Index (9/30/14)			***	
Adage Capital Mgmt (4/30/04) US Large Cap Core Equity 305,688,370 21.2%		US Large Cap Core Equity		
Earnest Partners Mid Cap (8/27/2018) US Midcap Value Equity 28,630,893 2.0% Vanguard Mid Cap (2/2/17) US Midcap Core Equity 28,630,893 2.0% Small Cap Equity 28,630,893 2.0% Small Cap Equity 28,630,893 2.0% Ariel Small Cap (8/31/2018) US Small Cap Value Equity 32,226,504 2.2% Ariel Small Cap (8/31/2018) US Small Cap Equity 8,651,163 0.6% International Equity 333,908,389 23.5% Developed International Equity 24,010,130 17.2% Silchester International (4/30/06) Non-US DM/EM Value Equity 24,010,130 17.2% Silchester International (4/30/06) Non-US DM/EM Value Equity 12,444,607 11.3% GGG International (3/31/2020) Non-US DM Core Equity 12,444,607 11.3% GGG International (3/31/2021) Non-US DM Core Equity 14,300,207 11.3% Brown Capital (9/17/2021) Non-US DM Core Equity 14,317,228 13.% Brown Capital (9/17/2021) Non-US DM Core Equity 14,300,207 1.0% Emerging Markets SSGA China CF (1/7/2022) Non-US DM Core Equity 14,300,207 1.0% Vanguard FTSE Emerging Markets (2/2/17) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/3/108) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/3/108) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/3/108) Non-US EM Equity 39,630,311 2.7% Total Alternative Investments 65,363,508 4.5% Davidson Kempner (8/3/193) Credit Strategy 18,370,489 1.3% Total Alternative Investments 65,363,508 4.5% Davidson Kempner (8/3/193) Credit Strategy 18,370,489 1.3% Total Non-US EM Equity 4,537,444 0.3% Octagon Fund IV (10/3/12021) Credit Strategy 4,537,444 0.3% Octagon Fund IV (10/3/12021) Credit Strategy 5,566,526 1.7% Equity Long/Short 212,036 0.0% Multi-Strategy 4,537,444 0.3% Octagon Fund IV (10/3/12021) Credit Strategy 5,506,526 1.7% Equity 13,477 0.0% Multi-Strategy 6,022,274 0.4% Janus Multi-Strategy 1,503,450 1.1% Infer Partners 2006 (4/3/006) Private Equity 1,546,540 0.0% Infer Partners 2007 (1/3/107) Private Equity 1,546,540 0.0% Infer Partners	` ,		· · ·	
Vanguard Mid Cap (2/2/17)	Addge Supital Inglift (4/00/04)	co Large cup core Equity	000,000,070	21.270
Vanguard Mid Cap (2/2/17)	Earnest Partners Mid Cap (8/27/2018)	US Midcap Value Equity	40.463.580	2.8%
Small Cap Equity	,			
Artel Small Cap (8121/2018) Artisan Small Cap (9/25/2020) US Small Cap Value Equity 8,651,163 0.6% International Equity Developed International Equity Non-US DM/EM Value Equity 1248,010,130 17.2% Slichester International (4/30/05) Non-US DM/EM Value Equity 1248,010,130 17.2% Slichester International (4/30/05) Non-US DM/EM Value Equity 1248,010,130 17.2% Slichester International (3/31/2020) Non-US DM Core Equity 1248,010,130 11.3% AND Core Equity 127,847,105 1.9% Non-US DM Core Equity 14,300,207 1.0% Emerging Markets 10,394,207 Non-US DM Core Equity 14,300,207 1.0% Emerging Markets 10,398,260 6.3% SSGA China CF (1/7/2022) Non-US EM Equity Non-US EM Equity Non-US EM Equity 39,530,311 2.7% Vanguard FTSE Emerging Markets (2/2/17) Non-US EM Equity 39,530,311 2.7% Vanguard FTSE Emerging Markets (8/31/08) Non-US EM Equity 39,530,311 2.7% Vanguard FTSE Emerging Markets (2/2/17) Non-US EM Equity 44,648,657 3.1% Total Alternative Investments 103,966,677 7.2% Credit Strategies 55,363,508 4.5% Davidson Kempner (8/31/93) Credit Strategy 18,370,489 137 Ventures (1/2/31/2020) Credit Strategy 7,547,712 0.5% Shenkman Opp Crd (8/31/2021) Credit Strategy 38,341,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 38,391,132 2.7% Multi-Strategy 18,304,340 1.1% Multi-Strategy 19,443,47 10,0% Multi-Strategy 10,9% TIFF Partners 2007 (1/31/07) Private Equity 10,0% Multi-Strategy 10,9% TIFF Partners 2007 (1/31/07) Private Equity 10,0% TiFF Partners 2007 (1/31/07) Private Equit				,,,
Artel Small Cap (8121/2018) Artisan Small Cap (9/25/2020) US Small Cap Value Equity 8,651,163 0.6% International Equity Developed International Equity Non-US DM/EM Value Equity 1248,010,130 17.2% Slichester International (4/30/05) Non-US DM/EM Value Equity 1248,010,130 17.2% Slichester International (4/30/05) Non-US DM/EM Value Equity 1248,010,130 17.2% Slichester International (3/31/2020) Non-US DM Core Equity 1248,010,130 11.3% AND Core Equity 127,847,105 1.9% Non-US DM Core Equity 14,300,207 1.0% Emerging Markets 10,394,207 Non-US DM Core Equity 14,300,207 1.0% Emerging Markets 10,398,260 6.3% SSGA China CF (1/7/2022) Non-US EM Equity Non-US EM Equity Non-US EM Equity 39,530,311 2.7% Vanguard FTSE Emerging Markets (2/2/17) Non-US EM Equity 39,530,311 2.7% Vanguard FTSE Emerging Markets (8/31/08) Non-US EM Equity 39,530,311 2.7% Vanguard FTSE Emerging Markets (2/2/17) Non-US EM Equity 44,648,657 3.1% Total Alternative Investments 103,966,677 7.2% Credit Strategies 55,363,508 4.5% Davidson Kempner (8/31/93) Credit Strategy 18,370,489 137 Ventures (1/2/31/2020) Credit Strategy 7,547,712 0.5% Shenkman Opp Crd (8/31/2021) Credit Strategy 38,341,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 38,391,132 2.7% Multi-Strategy 18,304,340 1.1% Multi-Strategy 19,443,47 10,0% Multi-Strategy 10,9% TIFF Partners 2007 (1/31/07) Private Equity 10,0% Multi-Strategy 10,9% TIFF Partners 2007 (1/31/07) Private Equity 10,0% TiFF Partners 2007 (1/31/07) Private Equit	Small Cap Equity		40.877.667	2.8%
Artisan Small Cap (9/25/2020) US Small Cap Equity 338, 998, 389 23.5% Developed International Equity Sichester International (4/30/05) Non-US DM/EM Value Equity 152, 260, 982 1.8% Vanguard Developed Markets (10/31/14) Non-US DM Core Equity Non-US DM Core Equity 162, 484, 607 11.3% GQG International (3/31/2020) Non-US DM Core Equity 18, 117, 228 1.3% Brown Capital (9/17/2021) Non-US DM Core Equity 18, 117, 228 1.3% Non-US DM Core Equity 14, 300, 207 1.0% Emerging Markets Posspace Non-US DM Core Equity Non-US DM Core Equity 14, 300, 207 1.0% Emerging Markets Non-US DM Core Equity Non-US DM Core Equity 14, 300, 207 1.0% Emerging Markets Posspace Non-US EM Equity Non-US		US Small Cap Value Equity		
International Equity				
Developed International Equity 248,010,130 17,2%	γ (************************************		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Developed International Equity 248,010,130 17.2%	International Equity		338,908,389	23.5%
Silchester International (4/30/05) Non-US DM/EM Value Equity 25,260,982 1.8% Vanguard Developed Markets (10/31/14) Non-US DM Core Equity 162,484,607 11.3% GQG International (3/31/2020) Non-US DM Core Equity 17,284,7105 1.9% Channing International (9/15/2021) Non-US DM Core Equity 18,117,228 1.3% Brown Capital (9/17/2021) Non-US DM Core Equity 14,300,207 1.0% Emerging Markets 90,898,260 6.3% SSGA China CF (17/2022) Non-US EM Equity 39,630,311 2.7% Non-US EM Equity 39,646,677 7.2% Non-US EM Equity 39,646,677 7.2% Non-US EM Equity 39,646,677 7.2% Non-US EM Equity 7,547,712 0.5% Non			248,010,130	17.2%
Vanguard Developed Markets (10/31/14) Non-US DM Core Equity 162,484,607 11,3% GQG International (3/31/2020) Non-US DM Core Equity 27,847,105 1.9% Channing International (9/15/2021) Non-US DM Core Equity 18,117,228 1.3% Brown Capital (9/17/2021) Non-US DM Core Equity 14,300,207 1.0% Seminary of the control of the con		Non-US DM/EM Value Equity	25,260,982	1.8%
GQĞ International (3/31/2020) Non-US DM Core Equity 18,117,228 1.3% Brown Capital (9/17/2021) Non-US DM Core Equity 18,117,228 1.3% Brown Capital (9/17/2021) Non-US DM Core Equity 14,300,207 1.0% Emerging Markets 90,898,260 6.3% SSGA China CF (1/7/2022) Non-US EM Equity 6,619,292 0.5% Vanguard FTSE Emerging Markets (2/2/17) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 39,630,311 2.7% US EM Equity 39,66,677 7.2% Credit Strategies 65,365,08 4.5% Davidson Kempner (8/31/393) Credit Strategy 18,370,489 1.3% 137 Vontures (12/31/2020) Credit Strategy 7,547,712 0.5% Brightwood (5/31/2021) Credit Strategy 7,547,712 0.5% Brightwood (5/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2014) Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Equity Long/Short 12,036 0.0% Melvin (3/31/2021) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 15,003,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 15,003,450 1.1% AQR Risk Parity (2/21/17) Private Equity 13,247 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 106,768 0.0% TIFF Partners 2008 (1/30/06) Private Equity 106,768 0.0% TIFF Pa				11.3%
Channing International (9/15/2021) Non-US DM Core Equity 18,117,228 1,3% Brown Capital (9/17/2021) Non-US DM Core Equity 14,300,207 1.0% Emerging Markets 90,898,260 6.3% SSGA China CF (1/7/2022) Non-US EM Equity 6,619,292 0.5% Vanguard FTSE Emerging Markets (2/2/17) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 39,66,677 7.2% Credit Strategies 65,363,508 4.5% Davidson Kempner (8/31/93) Credit Strategy 18,370,489 1.3% 137 Ventures (1/2/31/2020) Credit Strategy 7,547,712 0.5% Brightwood (5/31/2021) Credit Strategy 4,537,434 0.3% Octagon Fund IV (10/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 25,066,526 1.7% Equity Long/Short 212,036 0.0% Multi-Strategy 38,391,132 2.7% Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 15,903,450 1.1% Janus Multi-Strat (3/31/20) Multi-Strategy 15,003,450 1.1% Private Equity 15,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 13,247 0.0% TIFF Partners 2006 (4/30/06) Private Equity 13,247 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2006 (4/30/08) Private Equity 106,768 0.0% T	• • • • • • • • • • • • • • • • • • • •		· · ·	1.9%
SSGA China CF (1/7/2022)	Channing International (9/15/2021)	Non-US DM Core Equity	18,117,228	1.3%
SSGA China CF (1/7/2022)				1.0%
SSGA Chia CF (1/7/2022) Non-US EM Equity 39,630,311 2.7% Vanguard FTSE Emerging Markets (2/2/17) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 44,648,657 3.1% Total Alternative Investments 103,966,677 7.2% Credit Strategies 65,363,508 4.5% Oavidson Kempner (8/31/93) Credit Strategy 18,370,489 1.3% 137 Ventures (12/31/2021) Credit Strategy 7,547,712 0.5% Brightwood (5/31/2021) Credit Strategy 4,537,434 0.3% Octagon Fund IV (10/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 9,841,347 0.7% Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Multi-Strategy 38,391,132 2.7% Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 16,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,465,408 1.1% Private Equity 13,247 0.0% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 13,247 0.0% TIFF Partners 2007 (1/31/07) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 193,3421 0.1% Denham Commodity Fund V (6/30/08) Private Equity 1,514,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 5,043,226 0.3% Bessemer XI (2/28/2021) Private Equity 9,872,091 0.7% (1/28/2021) Private Equity 9,872,091 0.7% (1/28/2021) Private Equity 9,848,651 0.2% (1/29/2021) Private Equity 9,848,651 0.6% (KK Americas XII (10/31/17) Private Equity 9,348,653 0.6% (1/31/15) 0.6%			, , ,	
SSGA China CF (1/7/2022) Non-US EM Equity 39,630,311 2.7% Vanguard FTSE Emerging Markets (2/2/17) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 44,648,657 3.1% Total Alternative Investments 103,966,677 7.2% Credit Strategies 65,363,508 4.5% Davidson Kempner (8/31/93) Credit Strategy 18,370,489 1.3% 137 Ventures (12/31/2020) Credit Strategy 7,547,712 0.5% Brightwood (5/31/2021) Credit Strategy 4,537,434 0.3% Octagon Fund IV (10/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 25,066,526 1.7% Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 6,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,625,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,665,408 1.1% Private Equity 13,247 0.0% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners 2007 (1/31/07) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 9,872,091 0.7% Denham Commodity Fund I (6/30/08) Private Equity 9,872,091 0.7% Denham Commodity Fund I (6/30/08) Private Equity 9,872,091 0.7% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 9,872,091 0.7% Denham Commodity Fund I (6/30/08) Private Equity 9,872,091 0.7% Denham Commodity Fund I (10/31/14) Private Equity 9,872,091 0.7% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% Denham Commodity Fund I (10/31 Private Equity 9,872,091 0.7% Denham Commodity Fund I (10/31 Private Equity 9,872,091 0.7% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% Denham Commodity Fund I (10/31 Private Equity 9,872,091 0.7% Denham Commodity Fund I (10/31 Private Equity 9,872,091 0.7% Denha	Emerging Markets		90,898,260	6.3%
Vanguard FTSE Emerging Markets (2/2/17) Non-US EM Equity 39,630,311 2.7% WGI Emerging Markets (8/31/08) Non-US EM Equity 44,648,657 3.1% Total Alternative Investments 103,966,677 7.2% Credit Strategies 65,363,508 4.5% Davidson Kempner (8/31/93) Credit Strategy 18,370,489 1.3% 137 Ventures (12/31/2020) Credit Strategy 7,547,712 0.5% Brightwood (5/31/2021) Credit Strategy 4,537,434 0.3% Octagon Fund IV (10/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 25,066,526 1.7% Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Multi-Strategy 38,391,132 2.7% Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 15,903,450 1.1% Private Equity 16,465,408 1.1% Private Equity 38,663 <td></td> <td></td> <td>· · ·</td> <td></td>			· · ·	
WGI Emerging Markets (8/31/08) Non-US EM Equity 44,648,657 3.1%	SSGA China CF (1/7/2022)	Non-US EM Equity	6,619,292	0.5%
WGI Emerging Markets (8/31/08) Non-US EM Equity 44,648,657 3.1%	Vanguard FTSE Emerging Markets (2/2/17)	Non-US EM Equity	39,630,311	2.7%
Total Alternative Investments Credit Strategies 65,363,508 4.5% Davidson Kempner (8/31/93) Credit Strategy 18,370,489 1.3% 137 Ventures (12/31/2020) Credit Strategy 7,547,712 0.5% Brightwood (5/31/2021) Credit Strategy 7,547,712 0.5% Brightwood (5/31/2021) Credit Strategy 9,841,347 0.7% Cotagon Fund IV (10/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 25,066,526 1.7% Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Multi-Strategy 38,391,132 2.7% Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 16,465,408 1.1% Private Equity 157,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 157,777,228 10.9% TIFF Partners 2006 (4/30/06) Private Equity 13,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2006 (4/30/06) Private Equity 973,421 0.1% TIFF Partners 2006 (4/30/06) Private Equity 1,647,55 0.1% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 9,872,091 0.7% 6KR Americas XII (10/31/17) Private Equity 9,884,854 0.6% KKR Americas XII (10/31/17) Private Equity 9,248,651 0.2% Carlyle Strategic IV (11/30/16) Private Equity 9,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 9,248,651 0.2% Carlyle Strategic IV (11/30/16) Private Equity 9,348,854 0.6% CARIVE STRATEGIE IV (11/30/16) Private Equity 9,348,854 0.6% CARIVE STRATEGIE IV (11/30/16) Private Equity 9,348,854 0.6% CARIVE STRATEGIE IV (11/30/16) Private Equity 9,348,854		Non-US EM Equity	44,648,657	
Credit Strategies 65,363,508 4.5% Davidson Kempner (8/31/93) Credit Strategy 18,370,489 1.3% 137 Ventures (12/31/2020) Credit Strategy 7,547,712 0.5% Brightwood (5/31/2021) Credit Strategy 4,537,434 0.3% Octagon Fund IV (10/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 25,066,526 1.7% Shenkman Opp Crd (8/31/2018) Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Multi-Strategy 38,391,132 2.7% Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 6,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,465,408 1.1% Private Equity 15,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 10,768 0.0%				
Davidson Kempner (8/31/93) Credit Strategy 18,370,489 1.3% 137 Ventures (12/31/2020) Credit Strategy 7,547,712 0.5% Brightwood (5/31/2021) Credit Strategy 4,537,434 0.3% Octagon Fund IV (10/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 25,066,526 1.7%	Total Alternative Investments		103,966,677	7.2%
137 Ventures (12/31/2020) Credit Strategy 7,547,712 0.5% Brightwood (5/31/2021) Credit Strategy 4,537,434 0.3% Octagon Fund IV (10/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 25,066,526 1.7% Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Multi-Strategy 38,391,132 2.7% Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 6,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,465,408 1.1% Private Equity 13,247 0.0% TIFF Partners IV (1/31/01) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (4/30/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 52,038 <	Credit Strategies		65,363,508	4.5%
Brightwood (5/31/2021) Credit Strategy 4,537,434 0.3% Octagon Fund IV (10/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 25,066,526 1.7%	Davidson Kempner (8/31/93)	Credit Strategy	18,370,489	1.3%
Octagon Fund IV (10/31/2021) Credit Strategy 9,841,347 0.7% Shenkman Opp Crd (8/31/2018) Credit Strategy 25,066,526 1.7% Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Multi-Strategy 38,391,132 2.7% Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 6,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,465,408 1.1% Private Equity 157,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2008 (1/31/08) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity	137 Ventures (12/31/2020)		7,547,712	0.5%
Shenkman Opp Crd (8/31/2018) Credit Strategy 25,066,526 1.7%	Brightwood (5/31/2021)		4,537,434	0.3%
Equity Long/Short 212,036 0.0% Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Multi-Strategy 38,391,132 2.7% Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 6,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,465,408 1.1% Private Equity 157,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 8,348,854 0.6%	Octagon Fund IV (10/31/2021)	Credit Strategy	9,841,347	0.7%
Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Multi-Strategy 38,391,132 2.7% Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 6,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,465,408 1.1% Private Equity 157,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28	Shenkman Opp Crd (8/31/2018)	Credit Strategy	25,066,526	1.7%
Melvin (3/31/2021) Equity Long/Short 212,036 0.0% Multi-Strategy 38,391,132 2.7% Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 6,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,465,408 1.1% Private Equity 157,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28				
Multi-Strategy 38,391,132 2.7% Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 6,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,465,408 1.1% Private Equity 157,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3%	Equity Long/Short		212,036	0.0%
Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 6,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,465,408 1.1% Private Equity 157,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%	Melvin (3/31/2021)	Equity Long/Short	212,036	0.0%
Citadel (12/29/2022) Multi-Strategy 15,903,450 1.1% AQR Risk Parity (2/21/17) Multi-Strategy 6,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,465,408 1.1% Private Equity 157,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%				
AQR Risk Parity (2/21/17) Multi-Strategy 6,022,274 0.4% Janus Multi-Strat (3/31/20) Multi-Strategy 16,022,274 1.1% Private Equity 157,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%	<u> </u>			
Danus Multi-Strat (3/31/20) Multi-Strategy 16,465,408 1.1%	,			
Private Equity 157,777,228 10.9% TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%	• · · · · · ·	6,5		
TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%	Janus Multi-Strat (3/31/20)	Multi-Strategy	16,465,408	1.1%
TIFF Partners IV (1/31/01) Private Equity 13,247 0.0% TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%				
TIFF Partners V (4/30/04) Private Equity 38,663 0.0% TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%			, ,	
TIFF Partners 2006 (4/30/06) Private Equity 106,768 0.0% TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%				
TIFF Partners 2007 (1/31/07) Private Equity 973,421 0.1% TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%				
TIFF Partners 2008 (1/31/08) Private Equity 2,235,654 0.2% Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%				
Denham Commodity Fund V (6/30/08) Private Equity 1,614,755 0.1% Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%	, ,	. ,	•	
Clayton, Dubilier & Rice Fund IX Credit (10/31 Private Equity 52,038 0.0% Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%			• •	
Clayton, Dubilier & Rice Fund IX (5/31/14) Private Equity 9,872,091 0.7% 645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%				
645 Ventures (8/31/2020) Private Equity 5,042,226 0.3% Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%				
Bessemer XI (2/28/2021) Private Equity 2,948,651 0.2% IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%			• •	
IVP XVII (2/28/2021) Private Equity 6,823,224 0.5% Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%	,	. ,		
Carlyle Strategic IV (11/30/16) Private Equity 8,348,854 0.6% KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%	,		, ,	
KKR Americas XII (10/31/17) Private Equity 12,115,013 0.8%				
			• •	
HIG Advantage Buyout (8/31/18) Private Equity 9,696,578 0.7%	,			
	HIG Advantage Buyout (8/31/18)	Private Equity	9,696,578	U./%

Manager	Asset Class	Market Value (\$)	% of Total Fund
Carlyle Partners VII (1/3/2019)	Private Equity	11,334,152	0.8%
Apollo Investment Fund IX (3/14/2019)	Private Equity	7,631,504	0.5%
Silver Lake Partners (6/11/2018)	Private Equity	12,258,001	0.9%
General Atlantic (12/31/19)	Private Equity	9,818,292	0.7%
CINVEN Fund VII (1/31/19)	Private Equity	9,618,068	0.7%
Broadway Strategic (6/30/19)	Private Equity	1,840,076	0.1%
Spark Capital (5/31/19)	Private Equity	2,618,314	0.2%
Spark Capital VII (2/15/22)	Private Equity	968,142	0.1%
Shine Capital (4/30/21)	Private Equity	3,692,129	0.3%
Spark Growth III (2/29/20)	Private Equity	9,758,055	0.7%
Spark Growth IV (2/15/22)	Private Equity	1,508,932	0.1%
Lux Opp (5/31/21)	Private Equity	3,564,668	0.2%
Lux Ventures (5/31/21)	Private Equity	3,775,527	0.3%
Vepf VIII (02/28/2023)	Private Equity	1,263,642	0.1%
Vista Equity Partners (6/30/2018)	Private Equity	10,410,939	0.7%
Variant (5/31/21)	Private Equity	1,655,887	0.1%
SOMA CAP III (10/31/21)	Private Equity	4,775,795	0.3%
BVP India (1/4/2022)	Private Equity	1,403,922	0.1%
DVF IIIula (1/4/2022)	Filvate Equity	1,403,322	U. 1 /0
Private Real Assets		55,122,451	3.8%
Grain Communications (12/31/2020)	Private Real Assets	2,913,490	0.2%
Lazard Global Infr (9/25/20)	Public Real Assets	14,922,110	1.0%
ITE Rail (1/31/20)	Private Real Assets	11,183,274	0.8%
JPMorgan GTIF (2/29/20)	Private Real Assets	6,437,447	0.4%
CGI (5/31/22)	Private Real Assets	9,353,231	0.6%
Warburg Energy (5/31/14)	Private Real Assets	4,150,007	0.3%
LBA Realty Fund IV	Private Real Assets	492,956	0.0%
SRI Nine REIT (3/31/08)	Private Real Assets	69,347	0.0%
WCP Real Estate Fund II (11/30/08)	Private Real Assets	743,921	0.1%
GS Renew PWR LLC (8/31/2018)	Private Real Assets	4,856,668	0.3%
G3 Renew F WR LLC (6/31/2018)	1 Hvate Real Assets	4,000,000	0.070
Total Fixed		164,660,529	11.4%
CIFC Sr. Secured Corp Fund (8/31/2018)	Corporate Bonds	33,825,128	2.3%
PIMCO Income Fund (7/24/17)	Aggregate Bonds	24,628,107	1.7%
Prudential US High Yield (2/2/17)	High Yield Bonds	22,743,013	1.6%
SSGA 1-3 YR UST (7/31/19)	Short Duration Bonds	37,055,105	2.6%
SSGA US Agg (7/31/19)	Aggregate Bonds	25,813,115	1.8%
Xponance Credit (11/04/2022)	Aggregate Bonds	20,596,061	1.4%
			,
Cash Account		8,237,330	0.6%
Secondary Cash (09/30/2022)		6,453,994	0.4%
,			2
Total Managed Assets		1,441,178,184	100.0%
Allocation to Index or Enhanced Index Stra	ntegies		
		Growth Pool	
% of Total:		33.6%	

UNIVERSITY OF MIAMI - GROWTH POOL

Portfolio Liquidity Restrictions: Based on Market Value



UNIVERSITY OF MIAMI - GROWTH POOL

Inception to Date Performance vs. Relevant Benchmark(s) Periods ending - May 31, 2024 Net of Fees

Total Returns (%) - Annualized if Greater than 1	Year		
Large/Mid/All Cap Equity	ROR	Value Added (+/-)	Years
Vanguard Institutional Index (9/30/14)	12.46	-0.33	9.7
S&P 500	12.79		9.7
Adage Capital Mgmt (4/30/04)	12.93	2.69	20.1
S&P 500	10.23		20.1
Earnest Partners Mid Cap (8/27/2018)	10.30	1.63	5.8
Russell Midcap	8.67		5.8
Vanguard Mid Cap (2/2/17)	10.05	-0.02	7.3
CRSP MidCap Index	10.07		7.3
Small Cap Equity			
Ariel Small Cap (8/31/2018)	5.65	1.14	5.8
Russell 2000 Value	4.50		5.8
Artisian Small Cap (9/25/2020)	-1.31	-6.11	3.7
Russell 2000 Growth	4.80		3.7
Developed International Equity			
Silchester International (4/30/05)	7.58	2.22	19.1
MSCI EAFE Value ND	5.36		19.1
GQG International (3/31/20)	16.18	4.25	4.2
MSCI ACWI ex US	11.93		4.2
Vanguard Developed Markets (10/31/2014)	5.68	-0.25	9.6
FTSE Dev All Cap ex US	5.93		9.6
Brown Capital (9/17/21)	-7.54	-5.64	2.7
MSCI ACWI Small Cap ex US	-1.90		2.7
Channing Intl (9/15/21)	2.55	-0.03	2.7
MSCI EAFE ND	2.58		2.7
Emerging Markets			
Vanguard FTSE Emerging Markets (2/2/17)	4.72	0.35	7.3
MSCI Emerging Markets ND	4.38		7.3
WGI Emerging Markets (8/31/08)	8.64	5.61	15.8
MSCI Emerging Markets ND	3.03		15.8
SSGA China CF (1/7/22)	-10.41		2.4
Credit Strategies			
Davidson Kempner (8/31/93)	8.29	-0.20	30.8
HFR Event-Driven	8.49	4.40	30.8
Shenkman Opp Crd (8/31/2018)	6.76	1.16	5.8
HFRI ED: DIST RS (USD)	5.61		5.8
137 Ventures (12/31/20)	3.03		3.4
Brightwood (5/31/21)	9.43		3.0
Octagon Fund IV (10/31/21)	13.16		2.6
Multi-Strategy	2.86	0.72	4.2
Janus Multi-Strat (3/31/20)	2.14	0.72	4.2
FTSE 1-Month T-Bill Citadel (12/29/2022)	14.73		1.4
Fixed Income	14.73		1.4
SSGA US Agg (7/31/19)	-0.77	-0.29	4.8
BB Barclays U.S. Aggregate	-0.77	-0.23	4.8
Ishares 7-10 Year (11/20/2023)	0.52		7.0
Pimco Income Fund (7/24/17)	3.21	2.55	6.9
BB Barclays U.S. Aggregate	0.66	2.00	6.9
Prudential US High Yield (2/2/17)	4.45	0.10	7.3
BB Barclays U.S. Corporate High Yield	4.36	VIIV	7.3
CIFC Sr. Secured Corp Fund (8/31/18)	4.49	-0.73	5.8
S&P/LTSA Lev Loan Index	5.23	3.1. 🗸	5.8
SSGA 1-3 YR UST (7/31/19)	0.84	-0.12	4.8
BB Barc US Agg Treasury 1-3 Yrs	0.96	J.1.=	4.8
Vangd Long-Term UST (5/14/24)	-1.27		
Xponance Credit (11/04/2022)	4.31	-0.14	0.0
BB Barclays U.S. Aggregate	4.44	J.1.1	0.0

University of Arizona Financial Report

Account Activity Report

Evelyn F. McKnight Chair for Learning and Memory in Aging

Research, Innovation and Impact

Account Number 40-00-2093

Established 12/30/2010

Activity from July 1, 2023 to June 30, 2024

FUND PERFORMANCE	
Beginning market value at 07/01/2023	\$ 933,967.18
Investment performance	69,882.97
Endowment payout	(39,124.44)
Endowment fee	(9,373.82)
New gifts and additions	0.00
Ending market value at 06/30/2024	\$ 955,351.89
Historical Gift Value at 06/30/2024	\$ 1,000,000.00
PROJECTED PAYOUT FY 2024-25*	\$ 40,349.88

^{*}This amount may be wholly or partially capitalized into the fund as specified in the endowment agreement.

The Payout is the annual distribution from the endowment for the fund's purpose and is equal to 4.25% of the average fair value of the corpus of an endowment at the end of the 12 quarterly periods within the three previous calendar year-ends. The Historical Gift Value is the sum of all gifts received into an endowed fund since its creation. Additional information can be found on page 7 of the Annual and Endowment Report.

Questions? Please contact donorservices@uafoundation.org or 520-621-5491.

Account Activity Report

E. F. McKnight Brain Institute Endowment

College of Science

Department of Psychology

Account Number 40-10-4500

Established 6/24/2014

Activity from July 1, 2023 to June 30, 2024

FUND PERFORMANCE	
Beginning market value at 07/01/2023	\$10,467,549.49
Investment performance	801,843.74
Endowment payout	(445,464.90)
Endowment fee	(106,736.57)
New gifts and additions	262,839.55
Ending market value at 06/30/2024	\$10,980,031.31
Historical Gift Value at 06/30/2024	\$ 9,719,296.90
PROJECTED PAYOUT FY 2024-25*	\$ 463,747.92

^{*}This amount may be wholly or partially capitalized into the fund as specified in the endowment agreement.

The Payout is the annual distribution from the endowment for the fund's purpose and is equal to 4.25% of the average fair value of the corpus of an endowment at the end of the 12 quarterly periods within the three previous calendar year-ends. The Historical Gift Value is the sum of all gifts received into an endowed fund since its creation. Additional information can be found on page 7 of the Annual and Endowment Report.

Questions? Please contact donorservices@uafoundation.org or 520-621-5491.



University of Arizona Foundation

McKnight Brain Inst MV and HGV

For the period 01-01-2024 through 11-30-2024

Endowment Number	Endowment Name	Historic Gift Value	Fair Value 11/30/24	Fair Value 12/31/23	College
10-10-4500	E. F. McKnight Brain Inst/Endowed	9,789,517.85	11,208,835.32	10,781,947.56	9,789,517.85 11,208,835.32 10,781,947.56 SCNC - College of Science
		9,789,517.85	11,208,835.32 10,781,947.56	10,781,947.56	

16

Page 1 of 1

Report Date: 12-16-2024



.024 Manager/Style	GMO: PIMCO RAE Large: River Road: Sequoia Capital: FEG Select Biotech; S&P 500 Index Fund				ADV; Asia Alts; Africa Development; Cartesian; ECI; OpCapita; DFI; Menlo; Atlas; RRE; Summit; GGV; CD&R Berkshire Staple Street: Mason Wells; Silver Oak: Angeles: Timber Bay; WindRose: Rubicon Technology; Accel: FEG Private Opp				Edge; Scout; Pelican; Rockland; Farallon; Harbert; Iron Point; Singerman; Westport; Homestead; TRG; Lime Rock; Tembo					PIMCO Income Fund; Vanguard Treasury	AG Direct Lending; Gramercy; Merit; Falcon; Owl Rock				Elliott; HBK; Taconic; Junto; Atalan; First Eagle Gold			٥	
11/30/2024	23.6%	8.5%	4.7%	4.9%	21.5%	63.2%	%19		10.4%	10.4%	13%		3.9%	7.2%	2.3%	13.4%	%91		13.0%	13.0%	%11	100.0%	
Asset Class	Equity US	International Developed	Global	Emerging Markets	Private	Total Equity	•	Real Assets	Private	Total Real Assets		Fixed Income	Cash	Public	Private Credit	Total Fixed Income		Diversifying Strategies	Diversifying Strategies	Total Diversifying Strategies		Grand Total	"

Note: Fiscal 2025 target allocations are shown in italics.

University of Arizona Evelyn F. McKnight Institute Annual Report 2024

Projected Budget – July 1, 2025 – June 30, 2026

Evelyn F. McKnight Brain Institute	Budget
Personnel	\$515,000
Operations	\$100,000
Total	\$615,000

Projected Expenditures – July 1, 2025 – June 30, 2026

Evelyn F. McKnight Brain Institute	Budget
Personnel	\$515,000
Operations	\$100,000
Total	\$615,000

Permanent Endowment Expenditures

The Evelyn F. McKnight Institute account distributes funds from the permanent endowment to cover personnel, travel and operational expenses.

Permanent Endowment Unmatched Balance

The UA Foundation current unmatched balance is \$36,482. The UA Foundation will continue to direct all undesignated gifts to the McKnight Endowment until the match is received.

Beginning Balance on January 1, 2024	\$9,651,939
Additional Contribution	\$ 137,578
Ending Balance on November 30, 2024	\$9,789,518

Historic Gift Value McKnight \$4,826,000 Historic Gift Value UAF Match \$4,963,518

University of Alabama at Birmingham Financial Report

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees) Report Period: 10/1/23-9/30/24

Financi	ial Summary Format	
UAB		
Summa	ary for 12 months ended	
Accour	nt Name: All endowments benefitting the Evelyn	F. McKnight Brain Institute
A.	Beginning Balance on <u>10/1/2023</u>	\$ <u>19,129,699</u>
B.	Investment Growth	\$ 3,075,330
C.	Distributions	\$ (823,507)
D.	Additional Contribution	\$ <u>260,991</u>
E.	Ending Balance on <u>9/30/2024</u>	\$ 21,642,513
F.	Unmatched Balance (if applicable)	\$

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees) Report Period: 10/1/23-9/30/24

Financ	cial Summary Format	
UAB		
Summ	ary for 12 months ended	
Accou	nt Name: <u>Evelyn F. McKnight Brain Institute E</u>	ndowed Support Fund
A.	Beginning Balance on _10/1/2023	\$ <u>5,877,552</u>
B.	Investment Growth	\$ 938,848
C.	Distributions	\$ (252,052)
D.	Additional Contribution	\$
E.	Ending Balance on _9/30/2024	\$ <u>6,564,348</u>
F.	Unmatched Balance (if applicable)	\$

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees) Report Period: 10/1/23-9/30/24

•

Financ	ial Summary Format	
<u>UAB</u>		
Summa	ary for 12 months ended9/30/2024	
Accoun	nt Name: Evelyn F. McKnight Endowed Chair for	Learning and Memory in Aging
A.	Beginning Balance on <u>10/1/2023</u>	\$ _1,695,060
B.	Investment Growth	\$ 270,760
C.	Distributions	\$ (72,691)
D.	Additional Contribution	\$
E.	Ending Balance on _9/30/2024	\$ <u>1,893,129</u>
F.	Unmatched Balance (if applicable)	\$

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees) Report Period: 10/1/23-9/30/24

Financial Summary Format UAB _____ Summary for 12 months ended 9/30/2024 Account Name: Geropsychiatry Research Chair Beginning Balance on _10/1/2023_____ \$ 2,132,865 A. В. **Investment Growth** \$ 340,692 C. Distributions \$ (91,465) Additional Contribution D. E. Ending Balance on _9/30/2024_____ \$ 2,382,092 F. Unmatched Balance (if applicable)

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees) Report Period: 10/1/23-9/30/24

Financ	cial Summary Format	
UAB		
Summ	ary for 12 months ended	
Accou	nt Name: F. Cleveland Kinney Endowed Chair in	n Geriatric Psychiatry
A.	Beginning Balance on <u>10/1/2023</u>	\$ <u>1,680,007</u>
B.	Investment Growth	\$ <u>268,355</u>
C.	Distributions	\$ (72,045)
D.	Additional Contribution	\$
E.	Ending Balance on <u>9/30/2024</u>	\$ <u>1,876,317</u>
F.	Unmatched Balance (if applicable)	\$

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees) Report Period: 10/1/23-9/30/24

Financ	ial Summary Format	
<u>UAB</u>		
Summ	ary for 12 months ended	
Accou	nt Name: Warren Family Endowed Chair in Neur	rology
A.	Beginning Balance on <u>10/1/2023</u>	\$ <u>1,771,421</u>
B.	Investment Growth	\$ <u>282,957</u>
C.	Distributions	\$ (75,965)
D.	Additional Contribution	\$
E.	Ending Balance on <u>9/30/2024</u>	\$ <u>1,978,413</u>
F.	Unmatched Balance (if applicable)	\$

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees) Report Period: 10/1/23-9/30/24

Financ	ial Summary Format	
UAB		
Summa	ary for 12 months ended <u>9/30/2024</u>	
Accou	nt Name: Patsy W. and Charles A. Collat Endowe	ed Professorship in Neuroscience
A.	Beginning Balance on _10/1/2023	\$ <u>571,533</u>
B.	Investment Growth	\$ 91,294
C.	Distributions	\$ (24,510)
D.	Additional Contribution	\$
E.	Ending Balance on _9/30/2024	\$ <u>638,317</u>
F.	Unmatched Balance (if applicable)	\$

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees)

Report Period: 10/1/23-9/30/24

Financ	cial Summary Format	
<u>UAB</u>		
Summ	nary for 12 months ended	
Accou	int Name: Jarman F. Lowder Endowed Professors	ship in Neuroscience
A.	Beginning Balance on _10/1/2023	\$ <u>704,714</u>
B.	Investment Growth	\$ <u>112,567</u>
C.	Distributions	\$ (30,221)
D.	Additional Contribution	\$
E.	Ending Balance on _9/30/2024	\$ 787,060
F.	Unmatched Balance (if applicable)	\$

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees) Report Period: 10/1/23-9/30/24

Financ	cial Summary Format	
<u>UAB</u>		
Summ	ary for 12 months ended	
Accou	nt Name: Virginia B. Spencer Endowed Profes	sorship in Neuroscience
A.	Beginning Balance on <u>10/1/2023</u>	\$ <u>1,697,077</u>
B.	Investment Growth	\$ 271,082
C.	Distributions	\$ (72,777)
D.	Additional Contribution	\$
E.	Ending Balance on _9/30/2024	\$ <u>1,895,382</u>
F.	Unmatched Balance (if applicable)	\$

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees)

Report Period: 10/1/23-9/30/24

Financi	al Summary Format	
<u>UAB</u>		
Summa	ary for 12 months ended	
Accour	t Name: Rebecca Gale-Heersink Endowed Chair	
A.	Beginning Balance on <u>10/1/2023</u>	\$ <u>1,341,824</u>
B.	Investment Growth	\$ 237,195
C.	Distributions	\$ (65,183)
D.	Additional Contribution	\$ 250,000
E.	Ending Balance on <u>9/30/2024</u>	\$ <u>1,763,836</u>
F.	Unmatched Balance (if applicable)	\$

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees)

Report Period: 10/1/23-9/30/24

Financ	cial Summary Format	
<u>UAB</u>		
Summ	eary for 12 months ended 9/30/2024	
Accou	nt Name: Protective Life Endowed Chair in Hea	lthy Aging
A.	Beginning Balance on _10/1/2023	\$ <u>1,433,403</u>
B.	Investment Growth	\$ 225,761
C.	Distributions	\$ (56,982)
D.	Additional Contribution	\$ <u>10,991</u>
E.	Ending Balance on _9/30/2024	\$ <u>1,613,173</u>
F.	Unmatched Balance (if applicable)	\$

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees)

Report Period: 10/1/23-9/30/24

Financia	al Summary Format	
UAB		
Summa	ry for 12 months ended <u>9/30/2024</u>	
Accoun	t Name: Patsy W. and Charles Collat Scholar in N	euroscience Endowed Support Fund
A.	Beginning Balance on _10/1/2023	\$ <u>224,243</u>
B.	Investment Growth	\$ <u>35,819</u>
C.	Distributions	\$ (9,616)
D.	Additional Contribution	\$
E.	Ending Balance on _9/30/2024	\$ _\$250,446
F.	Unmatched Balance (if applicable)	\$

DEFINITIONS

DISTRIBUTION is the money transferred from the account to the spendable/operating account for the designated use.

BALANCE is the market value of the account as of the first or last day of the reporting year.

ADDITIONAL CONTRIBUTION is additional contribution by MBRF, the reporting institution, match etc.

INVESTMENT GROWTH (Loss) is the total undistributed interest, dividends, and realized and unrealized gains and losses.

Annual Report

McKnight Brain Research Foundation Sponsored Institutes and Research Programs (Include activity of all McKnight supported faculty and trainees) Report Period: 10/1/2023 – 9/30/2024

MCKNIGHT BRAIN INSTITUTE AT UAB

Cumulative Endowment Total

Book Value at 9/30/2024: \$16,524,073

Market Value at 9/30/2024: \$21,642,513

Projected Spendable Earnings for FY 2024/25: \$802,061

Evelyn F. McKnight Brain Institute Endowed Support Fund

Date Approved: 2/4/2011

Book Value at 9/30/2024: \$5,000,000

Market Value at 9/30/2024: \$6,564,348

Projected Spendable Earnings for FY 2024/25: \$256,663

Evelyn F. McKnight Endowed Chair for Learning and Memory in Aging

Date Approved: 10/1/2004

Current Occupant: Ronald M. Lazar, Ph.D.

Occupant Date: 9/15/2017

Book Value at 9/30/2024: \$1,500,000 Market Value at 9/30/2024: \$1,893,129

Projected Spendable Earnings for FY 2024/25: \$74,021

Geropsychiatry Research Chair

Date Approved: 6/28/1993

Designated Occupant: Junghee Lee, Ph.D.

Occupant Date: 3/1/2020

Book Value at 9/30/2024: \$1,222,896

Market Value at 9/30/2024: \$2,382,092

Projected Spendable Earnings for FY 2024/25: \$93,139

F. Cleveland Kinney Endowed Chair in Geriatric Psychiatry

Date Approved: 6/15/2007

Current Occupant: Karen L. Gamble, Ph.D.

Occupant Date: 11/4/2022

Book Value at 9/30/2024: \$1,503,940

Market Value at 9/30/2024: \$1,876,317

Projected Spendable Earnings for FY 2024/25: \$73,363

Warren Family Endowed Chair in Neurology

Date Approved: 6/15/2012

Current Occupant: David S. Geldmacher, M.D., FACP

Occupant Date: 11/4/2016

Book Value at 9/30/2024: 1,506,618

Market Value at 9/30/2024: \$1,978,413

Projected Spendable Earnings for FY 2024/25: \$77,355

Patsy W. and Charles A. Collat Endowed Professorship in Neuroscience

Date Approved: 4/4/2014

Current Occupant: Jeremy H. Herskowitz, Ph.D. Occupant Date: 11/8/2019

Book Value at 9/30/2024: \$500,000 Market Value at 9/30/2024: \$638,317

Projected Spendable Earnings for FY 2024/25: \$24,958

Jarman F. Lowder Endowed Professorship in Neuroscience

Date Approved: 6/15/2012

Current Occupant: Michelle Gray, Ph.D.

Occupant Date: 9/16/2022

Book Value at 9/30/2024: \$590,619

Market Value at 9/30/2024: \$787,060

Projected Spendable Earnings for FY 2024/25: \$30,774

Virginia B. Spencer Endowed Professorship in Neuroscience

Date Approved: 9/14/2012

Current Occupant: Craig Powell, M.D., Ph.D.

Occupant Date: 6/8/2018

Book Value at 9/30/2024: \$1,500,000

Market Value at 9/30/2024: \$1,895,382

Projected Spendable Earnings for FY 2024/25: \$74,109

Rebecca Gale-Heersink Endowed Chair

Date Approved: 6/7/2019

Current Occupant: Erik D. Roberson, Ph.D.

Occupant Date: 9/6/2019

Book Value at 9/30/2024: \$1,500,000 Market Value at 9/30/2024: \$1,763,836

Projected Spendable Earnings for FY 2024/25: \$68,965

Protective Life Endowed Chair in Healthy Aging

Date Approved: 6/4/2021

Current Occupant: Steven N. Austad, Ph.D.

Occupant Date: 9/1/2021

Book Value at 9/30/2024: \$1,500,000

Market Value at 9/30/2024: \$1,613,173

Projected Spendable Earnings for FY 2024/25: \$18,922

Patsy W. and Charles Collat Scholar in Neuroscience Endowed Support Fund

Date Approved: 4/10/2015

Book Value at 9/30/2024: \$200,000

Market Value at 9/30/2024: \$250,446

Projected Spendable Earnings for FY 2024/25: \$9,792

UAB EMBI Matching Funds				
Endowment Name	Date Established	Corpus as of 9/30/2024	Projected Spendable Earnings FY 24/25	
Warren Family Endowed Chair in Neurology	6/15/2012	1,506,618	\$77,355	
Patsy W. and Charles A. Collat Endowed Professorship in Neuroscience	4/4/2014	\$500,000	\$24,958	
Jarman F. Lowder Endowed Professorship in Neuroscience	6/15/2012	\$590,619	\$30,774	
Virginia B. Spencer Endowed Professorship in Neuroscience	9/14/2012	\$1,500,000	\$74,109	
Rebecca Gale-Heersink Endowed Chair	6/7/2019	\$1,500,000	\$68,965	
Protective Life Endowed Chair in Healthy Aging	6/4/2021	\$1,500,000	\$18,922	
Patsy W. and Charles A. Collat Scholar Endowed Support Fund	4/10/2015	\$200,000	\$9,792	
Total Matching Funds		\$7,297,237	\$304,875	
Remaining UAB Match		\$0		



INVESTMENT SUMMARY

What is the University of Alabama System Pooled Endowment Fund?

Endowed gifts to the University of Alabama at Birmingham are invested in the University of Alabama System Pooled Endowment Fund (UASPEF), along with individual endowed funds from the other two University of Alabama System campuses and related foundations.

Created in 1978, the UASPEF is managed by the Chancellor's Office and overseen by the Investment Committee of the University of Alabama System Board of Trustees. Strategically, the University of Alabama System's endowment portfolio is designed with a diversified asset allocation intended to lessen the effect of extreme market swings, while achieving a return greater than the endowment's spending policy (4.5%) and expected inflation over the long term.


GLOBAL EQUITY (STOCKS) – with the highest expected returns of the shown asset classes given its economic sensitivity, global equity is an important component for long-term investors. Within Global Equity, **PRIVATE EQUITY** is a key focus for the PEF going forward (28% target) and an area where the portfolio has had the greatest success adding value historically

REAL ASSETS (REAL ESTATE & RESOURCES) – an asset class intended to provide diversification benefits along with inflation protection

FIXED INCOME (BONDS) – a risk-reducing asset class that is intended to provide current income and preserve capital in periods of volatility in equity markets

DIVERSIFYING STRATEGIES (ALTERNATIVES)— an asset class intended to provide diversification benefits driven by active management

ASSET ALLOCATION as of June 30, 2024



KEY INVESTMENT PRINCIPLES


LONG-TERM PERSPECTIVE – the Endowment is positioned to take advantage of long-term investment themes within a diversified portfolio which may take multiple years and a full market cycle to bear fruit **VALUATION** – realizing opportunities to capture gains by rebalancing within stronger performing asset classes, while adding capital to those asset classes that may have been out of favor (buy low, sell high)

ACTIVE MANAGEMENT AND PRIVATE INVESTMENTS –

additional levers that have potential to add value and generate return objectives(buy low, sell high)

University of Miami Financial Report







Academic and Research Activities (2023-2024)

- Evelyn F. McKnight Brain Institute Neurocognitive Scholar
- Pathway Director, Neuroscience and Behavioral Science Pathway, University of Miami
- World Stroke Organization Brain and Heart Task Force
- Writing group, WSO Brain & Heart Task Force Position Statement on Ischemic Stroke
 Prevention in Patients Atrial Fibrillation and a Recent Ischemic Stroke, TIA, or Intracranial
 Hemorrhage
- Writing group, Cardiac Workup in Stroke Patients, Recommendations from the International Neurocardiology Consensus for Advancing Cardiac Workup after Stroke
- Writing group, New Devices for non-Atrial Fibrillation Stroke Prevention, Round Table of Academia and Industry for Stroke Prevention
- Section Editor, CME/Highlights, Stroke
- Consulting Editor, JACC:Advances
- Junior Editor, Journal of Clinical and Translational Investigation
- Acute Care Test Materials Development Committee for the USMLE, National Board of Medical Examiners
- Regional Conference Subcommittee, American Academy of Neurology

Conferences and Presentations (2023-2024)

- Speaker, "Aging Like a Pro" health education series
- Invited Speaker, International Stroke Conference 2024
- Invited Speaker, UM Neurology Update and Stroke Intensive, 2024



Annual Report

McKnight Brain Research Foundation
Sponsored Institutes and Research Programs
(Include activity of all McKnight supported faculty and trainees)
Report Period: ______May 31, 2024_____

Financial Summary

Evelyn F. McKnight Brain Institute at the University of Miami Miller School of Medicine

Summa	ry for 12	months ended May 31, 2024		_	
Accoun	it Name:	2002 Gift			
Α.		Beginning Balance on6/1/2023_		\$\$	13,955,336
B.		Investment Growth		\$	2,330,983
C.		Distributions		\$	599,818
D.		Additional Contribution		\$	0
59981	8+E.	Ending Balance on5/31/2024		\$	15,686,514
F.		Unmatched Balance (if applicable)			N204535A
Accoun	it Name:	2014 Gift			
A.	Beginn	ing Balance on <u>6/1/2023</u> _	\$	4,75	8,692
B.	B. Investment Growth		\$	79	94,856
C.	. Distributions		\$	20	04,535
D.	Additional Contribution		\$		0
E.	Ending Balance on5/31/2024		\$	5,34	19,013
F.	Unmatched Balance (if applicable) NA			NA	
	TOTAL	ENDING BALANCE ON 5/31/2024	\$	21,03	35,527



Account Name: Evelyn F. McKnight Neurocognitive Scholar

A. McKnight Scholar Gift

\$ 50,000

B. Match Gift *

\$ 70,000

*Remaining FY23 funding used this year in FY25

McKnight Budget Narrative 2024

In 2024 the EMBI stayed within budget, completed all programs and supported all researchers and staff as planned. The endowment due to good market conditions grew by 12.4% and thus return revenue was higher than the previous year. (\$804,353 vs \$737,121).

We received no additional endowment contribution this year.

Market conditions have caused an increase to scholar compassion above the \$100K. Remaining FY23 excess used this year in FY25.



Annual Report BUDGET for June 1, 2024 - May 31, 2025

Revenue from Endowment				804,353.00
Revenue for Scholar*				120,000.00
Total Revenue				924,353.00
Personnel				
Faculty	Role In Project	<u>CFB</u> Rate	Effort	
Tatjana Rundek, MD, PhD	Director	29.80%	25%	
Christian Agudelo, MD	Education Director	21.50%	15%	
Ihtsham Haq, MD	Assoc. Director, Chief Movement Disorders Assoc. Director, Chief	21.50%	10%	
Bonnie Levin, PhD	Neuropsychology	29.80%	25%	
Kunjan Dave, PhD	Neurology -Basic Science	29.80%	5%	
Tali Elfassy	Radiology	29.80%	5%	
Nicole Deuker, PhD	HIHG		50%	
Hong Jiang, MD, PhD	Neurology	21.50%	5%	
Jianhua Wang, MD, PhD	Neurology	21.50%	5%	
Sonya Kaur, PhD	Neuropsychology	29.80%	40%	
Anita Saporta, MD	Neurology		5%	
Christian Camargo, MD	Neurology		5%	
James Galvin, MD, MPH	Neurology		25%	
Lilah Besser, MD	Neurology		5%	
Subtotal Faculty Salary and CFB				456,469.00
Nicole Sur - McKnight Fellow	Neurology	N N		120,000.00
- Staff	Role in Project	CFB Rate	<u>Effort</u>	
Stacy Merritt	Director, Research Admin	40.50%	50%	
Sang Lee	Radiology	40.50%	5%	
Marti Flothmann	Manager, Digital Engagement	40.50%	20%	
Taylor Ariko	Neurology/BioMed PHD Student Clinical Research	40.50%	100%	
Marisa Modjeski	Coordinator	40.50%	50%	



Susan Fox-Rosellini	Exec. Director, Engagement and Admin	40.50%	40%	
Botagoz Aimagambetova	Asssitant Scientist	40.50%		
NeuroPsych Post Doc	Neuropsychology	40.50%		
NeuroPsych Post Doc	Neuropsychology	40.50%		
NeuroPsych Post Doc	Neuropsychology	40.50%		
NeuroPsych Post Doc	Neuropsychology	40.50%	25%	
Subtotal Staff and CFB				316,414.00
				print to the state of the state of
<u>Total Personnel</u>	ST ST MIGHT	,		892,883.00
Non Personnel Expenses				
SC08818 - Publication Costs (Excluding Copying)				
SC08801 - Registration Conferences & Seminars				
SC08803 - Dues & Memberships - Other				
SC08611 - Employee Domestic Travel				
SC08619 - Meetings - Subsistence				
SC08624 - Entertainment - F&B, Recep				
SC08852 - Monthly - Lines & Sets & SC08858 -				
Monthly - Voice Mail				
SC08103 - Advertising - Other				
SC08024 - Interdepart/ Intercomp - Service				
SC08235 - Computer Hardware & Software Non- Capital				
SC08218 - Clerical Supplies				
SC08219 - Instructional Supplies				
SC08229 - Photocopy, Publishing, & Print Supplies	T			
SC08200 - Chemicals/blood samples store/ship				
SC08011 - Interdepartmental / Intercompany - Animal Care Services - Internal				
SC08225 - Technical Supplies - Other				
Total Non Personnel Expenses				31,470.00
			•	
Grand Total Expenses				924,353.00

^{*}Final \$20K of the excess FY23 Scholar funds are being used in FY25




University of Miami - All Managed Assets Performance Periods Ending: May 31, 2024

Total Returns (Periods Greater Than 1 Year a	re Annualized)					
Growth Pool	Inception	1 Year (%)	3 Year (%)	5 Year (%)	7 Year (%)	10 Year (%)
Growth Pool Total Composite*	12/31/1990	17.68	4.65	9.42	8.02	6.77
Growth Pool Market Benchmark**	12/31/1990	19.14	3.88	9.17	7.81	6.98
Value (+/-)		-1.46	0.77	0.26	0.21	-0.20

Inception-to-Date Growth Pool Risk/Return as of May	31, 2024	
Growth Pool	15 Year Return	15 Year Standard Deviation
Growth Pool Total Composite	8.51	9.91
Growth Pool Market Benchmark	8.76	10.98

*Net of fee returns

Growth of Assets (\$ Millions)



^{**} A weighted average return derived by applying the target policy weights of each asset class to the performance of the asset class benchmarks



UNIVERSITY OF MIAMI - GROWTH POOL

Manager Structure - Market Values and Allocations Period Ending May 31, 2023

	Growth Pool		
Manager	Asset Class	Market Value (5)	% of Total Fund
.arge/Mid/All Cap Equity		565,173,917	39.2%
anguard Institutional Index (9/30/14)	US Large Cap Core Equity	190,391,074	13.2%
Adage Capital Mgmt (4/30/04)	US Large Cap Core Equity	305,688,370	21.2%
arnest Partners Mid Cap (8/27/2018)	US Midcap Value Equity	40,463,580	2.8%
/anguard Mid Cap (2/2/17)	US Midcap Core Equity	28,630,893	2.0%
imall Cap Equity		40.077.007	2.00/
Ariel Small Cap (8/31/2018)	US Small Cap Value Equity	40,877,667 32,226,504	2.8%
Artisan Small Cap (9/25/2020)	US Small Cap Equity	8,651,163	2.2% 0.6%
a tistii oman cap (o/20/2020)	os sman cap Equity	0,001,100	0.676
nternational Equity		338,908,389	23.5%
Developed International Equity		248,010,130	17.2%
ilchester International (4/30/05)	Non-US DM/EM Value Equity	25,260,982	1.8%
anguard Developed Markets (10/31/14)	Non-US DM Core Equity	162,484,607	11.3%
GQG International (3/31/2020)	Non-US DM Core Equity	27,847,105	1.9%
channing International (9/15/2021)	Non-US DM Core Equity	18,117,228	1.3%
rown Capital (9/17/2021)	Non-US DM Core Equity	14,300,207	1.0%
	otnika karanjaja ka		
merging Markets		90,898,260	6.3%
SGA China CF (1/7/2022)	Non-US EM Equity	6 640 202	0.50
anguard FTSE Emerging Markets (2/2/17)	Non-US EM Equity	6,619,292	0.5%
		39,630,311	2.7%
VGI Emerging Markets (8/31/08)	Non-US EM Equity	44,648,657	3.1%
otal Alternative Investments		103,966,677	7.2%
redit Strategies		65,363,508	4.5%
Pavidson Kempner (8/31/93)	Credit Strategy	18,370,489	1.3%
37 Ventures (12/31/2020)	Credit Strategy	7.547.712	0.5%
Brightwood (5/31/2021)	Credit Strategy	4,537,434	0.3%
Octagon Fund IV (10/31/2021)	Credit Strategy	9,841,347	0.7%
Shenkman Opp Crd (8/31/2018)	Credit Strategy	25,066,526	1.7%
mentinan opp ord (diotizo id)	Credit Strategy	23,000,320	1.770
quity Long/Short		212,036	0.0%
flelvin (3/31/2021)	Equity Long/Short	212,036	0.0%
lulti-Strategy		38,391,132	2.7%
itadel (12/29/2022)	Multi-Strategy	15,903,450	1.1%
QR Risk Parity (2/21/17)	Multi-Strategy	6,022,274	0.4%
anus Multi-Strat (3/31/20)	Multi-Strategy	16,465,408	1.1%
rivate Equity		157,777,228	10.9%
IFF Partners IV (1/31/01)	Private Equity	13,777,220	0.0%
TFF Partners V (4/30/04)	Private Equity	38.663	0.0%
TFF Partners 2006 (4/30/06)			
TFF Partners 2000 (4/30/06)	Private Equity	106,768	0.0%
TFF Partners 2008 (1/31/08)	Private Equity	973,421	0.1%
	Private Equity	2,235,654	0.2%
Penham Commodity Fund V (6/30/08)	Private Equity	1,614,755	0.1%
layton, Dubilier & Rice Fund IX Credit (10/31		52,038	0.0%
layton, Dubilier & Rice Fund IX (5/31/14)	Private Equity	9,872,091	0.7%
45 Ventures (8/31/2020)	Private Equity	5,042,226	0.3%
lessemer XI (2/28/2021)	Private Equity	2,948,651	0.2%
VP XVII (2/28/2021)	Private Equity	6,823,224	0.5%
Carlyle Strategic IV (11/30/16)	Private Equity	8,348,854	0.6%
CLOTH B	Driverto Equity	12,115,013	0.8%
KR Americas XII (10/31/17)	Private Equity	12,110,010	0.070



Manager	Asset Class	Market Value (5)	% of Total Fund
Carlyle Partners VII (1/3/2019)	Private Equity	11,334,152	0.8%
Apollo Investment Fund IX (3/14/2019)	Private Equity	7,631,504	0.5%
Gilver Lake Partners (6/11/2018)	Private Equity	12,258,001	0.9%
General Atlantic (12/31/19)	Private Equity	9,818,292	0.7%
CINVEN Fund VII (1/31/19)	Private Equity	9,618,068	0.7%
Broadway Strategic (6/30/19)	Private Equity	1,840,076	0.1%
Spark Capital (5/31/19)	Private Equity	2,618,314	0.2%
Spark Capital VII (2/15/22)	Private Equity	968,142	0.1%
Shine Capital (4/30/21)	Private Equity	3.692.129	0.3%
Spark Growth III (2/29/20)	Private Equity	9,758,055	0.7%
Spark Growth IV (2/15/22)	Private Equity	1,508,932	0.1%
Lux Opp (5/31/21)	Private Equity	3,564,668	0.2%
Lux Ventures (5/31/21)	Private Equity	3.775.527	0.3%
Vepf VIII (02/28/2023)	Private Equity	1,263,642	0.1%
Vista Equity Partners (6/30/2018)	Private Equity	10.410.939	0.7%
Variant (5/31/21)	Private Equity	1,655,887	0.1%
SOMA CAP III (10/31/21)	Private Equity	4.775,795	0.3%
BVP India (1/4/2022)	Private Equity	1,403,922	0.1%
DVI IIIdia (II-E022)	1 Tivate Equity	1,400,022	0.170
Private Real Assets		55.122.451	3.8%
Grain Communications (12/31/2020)	Private Real Assets	2.913.490	0.2%
Lazard Global Infr (9/25/20)	Public Real Assets	14,922,110	1.0%
TE Rail (1/31/20)	Private Real Assets	11,183,274	0.8%
JPMorgan GTIF (2/29/20)	Private Real Assets	6.437.447	0.4%
CGI (5/31/22)	Private Real Assets	9.353.231	0.6%
Warburg Energy (5/31/14)	Private Real Assets	4,150,007	0.3%
LBA Realty Fund IV	Private Real Assets	492,956	0.0%
SRI Nine REIT (3/31/08)	Private Real Assets	69.347	0.0%
WCP Real Estate Fund II (11/30/08)	Private Real Assets	743.921	0.1%
GS Renew PWR LLC (8/31/2018)	Private Real Assets	4.856.668	0.1%
23 MEIRERA L. Ray, proc. (ed. 22) porto.	Titolic real resets	4,000,000	0.370
Total Fixed		164,660,529	11.4%
CIFC Sr. Secured Corp Fund (8/31/2018)	Corporate Bonds	33,825,128	2.3%
PIMCO Income Fund (7/24/17)	Aggregate Bonds	24,628,107	1.7%
Prudential US High Yield (2/2/17)	High Yield Bonds	22,743,013	1.6%
SSGA 1-3 YR UST (7/31/19)	Short Duration Bonds	37,055,105	2.6%
SSGA US Agg (7/31/19)	Aggregate Bonds	25.813.115	1.8%
Kponance Credit (11/04/2022)	Aggregate Bonds	20,596,061	1.4%
description of the second	- 49-49-W - 51100	20,000,001	1.74 /0
Cash Account		8,237,330	0.6%
Secondary Cash (09/30/2022)		6,453,994	0.4%
Total Managed Assets		1,441,178,184	100.0%
Allocation to Index or Enhanced Index Stra	tegies		
		Growth Pool	
% of Total:		33.6%	

Proposal McKnight Brain Research Foundation Poster Reception San Diego, CA November 16, 2025

Background

Scientists from around the world gather annually at the Society for Neuroscience (SfN). SfN gives investigators an avenue to share their research. Beginning in 1971, the meeting has an annual attendance of thousands. It consists of poster sessions, symposia, and lectures presenting the latest findings on numerous topics. In the evening hours, social events provide a casual atmosphere in which researchers interested in a particular topic can network.

In 2008, the McKnight Brain Research Foundation began sponsoring a poster reception in conjunction with SfN. This gives investigators from the four McKnight Brain Institutes located at the University of Arizona, the University of Florida (UFL), the University of Miami and the University of Alabama at Birmingham (UAB), an opportunity to display their research and share their findings. SfN normally rotates between the cities of San Diego, California, Chicago, Illinois and Washington DC.

2024 Progress Report Chicago, IL

The 14th Annual McKnight Brain Research Foundation Poster Reception was held at the Hilton Chicago on Sunday, October 6th from 5:00 to 7:00 p.m. There were approximately 147 guests. There were 64 registered posters and 3 additional posters were added the night of the event. Abstracts received prior to the deadline were included in a poster competition. As space allowed, those submitting after the deadline were allowed to present their posters at the reception but were not included in the judging.

Registered posters included representation from all four McKnight Brain Institutes. Awards were presented to the following:

- 1st Place: UAB Co-Winners George Ling and Hannah Cowart
 - Dynamics of Default Mode Network Activity Linked to Processing Speed in Cognitively Healthy Oldest-Old
- 2nd Place: UFL Sabrina Zequeira
 - o Differential effects of chronic oral THC consumption in young and aged rats
- 3rd Place: Arizona Christopher Sterzinar
 - Age-related changes in medial prefrontal cortex-ventral hippocampus theta power interactions during a spatial working memory task
- Honorable Mention: UFL Barbara Balsamo
 - Alpha-Synuclein Aggregation Impairs Executive Function in Aging: Insights from a Prefrontal Cortex Mouse Model Study

- Honorable Mention: Miami Indy Diaz
 - Estrogen receptor-beta activation reduces cognitive deficits after stroke in middleaged female rats
- Honorable Mention: UFL

 Jose Rodriquez
 - Effects of chronic vagus nerve stimulation in aging

Attendees included scientists, researchers, clinicians, postdoctoral fellows, graduate, and undergraduate students. Prominent scientists from the National Institutes of Aging as well as neuroscientists at different stages of their careers interested in investigating age-related memory loss were in attendance. Posters were displayed and research was discussed throughout the evening.

A variety of hor d'oeuvres and drinks were provided. Funding budgeted for the drinks was over budget and a refund was issued from the hotel to the MBRF. The event fulfilled its goal of showcasing McKnight research being conducted at all levels and provided a venue where neuroscientists were able to network and discuss ideas centered on normative aging. Establishing new collaborations is always a possibility when researchers gather to discuss their projects.

Proposal

The 2025 McKnight Brain Research Foundation Poster Reception will be held in San Diego, CA on Sunday, November 16, 2025. Pending budget approval, an event will be planned at one of the local venues. While viewing abstracts from each of the McKnight Brain Research Institutes, a selection of beverages and hor d'oeuvres will be available for guests.

Records

Attendees will be required to sign-in and note the institute/organization they represent. Upon signing-in, attendees will receive two tickets for two free drinks. Using the ticket method will encourage everyone to sign-in and will ultimately provide documentation needed to verify attendance. The tickets will also allow the event planner to monitor expenses associated with beverage purchases, thus ensuring the bar tab does not exceed the budget.

Budget

Poster boards will be rented from an outside vendor. Food and beverage costs have been broken down into three options. Caterer will be consulted and the best menu will be selected at a cost that is within the approved budget. As previously noted, each attendee will receive 2 tickets for beverages thus providing a system to monitor beverage expenses. Using the approved budget, the catering expenses will be closely monitored to ensure no overages are incurred. The Appendix provides a 3-tiered budget proposal for consideration.

Appendix

Appendix	Tier 1	Tier 2	Tier 3
Standing podium and microphone set-up	\$ 800	\$ 800	\$ 800
Rental of Poster Boards 35 Double sided boards Size 4'x6' Price includes delivery, set-up and removal	6,000	6,000	6,000
Printing	300	300	300
Photographer	400	400	400
Office supplies	400	400	400
Event Planner (Hourly rate) \$50 x 55 estimated hours	2,750	2,750	2,750
Event Planner Expenses (Receipts to be provided for air, hotel 2 nights, meals, Uber to/from airport/hotel, airport parking)	1,400	1,400	1,400
Subtotal Miscellaneous Costs	12,050	12,050	12,050
Food Catering	Hot and cold appetizers	Hot and cold appetizers	Hot and cold appetizers
Beverage Catering	Small selection of beer and wine	Large selection of beer and wine	Open bar with wine, beer, and liquor
Subtotal Catering fees including service and tax	14,000	16,000	18,000
Estimated Grand Total	\$26,050	\$28,050	\$30,050



2025 MEMBERSHIP INVOICE

FOR THE PERIOD: January 1, 2025 - December 31, 2025

Organization Name:			
Address:			
Contact Name and Position:			
Email:			
Current Funding Priorities:			
Membership dues are determine other mechanisms focused on ag		rganization's total funding through grants, contracts, investment evious year.	ts, o
Annual Grants Made in Aging	Dues		
Less than \$99,999	\$550		
\$100,000 - \$249,999	\$950	Total Annual Grantmaking: \$	
\$250,000 - \$799,999	\$1,700	Total Grantmaking for Aging: \$	
\$800,000 - \$999,999	\$2,400	Total Ordinaming for Aging. \$	
\$1 million - \$2,999,999	\$4,000		
\$3 million - \$4,999,999	\$5,500	Dues Amount: \$	
\$5 million - \$10,999,999	\$8,000		
\$11 million - \$15,999,999	\$9,000		
\$16 million and above	\$10,000		
attend, as well as the Champio	n Fund.	ional donations to support the Funders Communities they ort from the philanthropic community for the 2025 reauthorizatio	n of
impact. Because the costs of run additional support generously pro	ning these coordinates on the coordinates of the co	nities for shared learning, collaboration, and co-funding to maximommunities are not covered by membership dues, GIA relies on If-selected Funders Community members who are committed to by. The average annual contribution to a Funders Community is	
Aging and Technology Donation A	Amount:	\$	
Family Caregiving Donation Amou	unt:	\$	
Housing Stability in Aging Donation		\$	
Multisector Plans for Aging Donat		<u>.</u>	
Rural Health and Aging Donation Serious Illness and End-of-Life Do		unt: \$	
Mental/Behavioral Health & Aging		•	
		pay-your-invoice. For ACH/Wire payment , contact Emily Baron be mailed to our address below. Contact Emily with any question	ıs.

PROPOSAL

Evelyn F. McKnight Clinical Translational Research Scholar Dinner American Academy of Neurology (76th AAN annual meeting) San Diego, Ca April 4-April 9, 2025

Objective

This is a proposal for funding the Evelyn F. McKnight Clinical Translational Research Scholars and mentors attendance at an Annual Dinner at the 76th AAN annual meeting in order to provide them with the opportunity to continue to learn about the McKnight Brain Research Foundation and its mission, meet and network with the Trustees, the other Scholars, the mentors, the leadership of the American Brain Foundation, AAN, and the McKnight Brain Institutes, and share opportunities for potential collaborations.

Background

The McKnight Brain Research Foundation and the American Brain Foundation created a scholarship award in order to advance research in cognitive aging in the clincal arena to benefit people with agerelated memory loss. 14 McKnight Clinical Translational Research Scholarships in Cognitive Aging and Age-related Memory Loss have been awarded to date.. The partnership between the McKnight Brain Research Foundation and the American Brain Foundation, in collaboration with the American Academy of Neurology, continues to advance clinical translational research for alleviation and treatment of age-related cognitive decline and memory loss.

As you know these Scholarships directly align with the University of Miami McKnight Brain Institutes mission to mentor and nurture the next generation of cognitive clinical and research scientists and promote collaboration and communication among research scientists, institutions, and organizations engaged in research in age-related memory loss.

The 1st Dinner was held at the 71st AAN meeting and the Scholars and their mentors were grateful to be able to meet in person and share ideas.

Proposal

Therefore, to continue this tradition, UM EMBI requests funding so as the *McKnight Clinical Translational Research Scholars in Cognitive Aging and Age-related Memory Loss* and mentors can meet and be exposed to each other at a <u>dinner</u>, Monday April 7, 2025 6-8 pm, during the 76th AAN annual meeting that will be held in San Diego from April 4 to 9, 2025.

This event offers an opportunity for a potential broader collaboration and integration of *McKnight Clinical Translational Research Scholars and mentors* with MBI institutions, ABF and AAN leadership, and MBRF trustees.

Currently, 14 McKnight Clinical Translational Research Scholars have been awarded and another 2 scholars will be awarded before the 2025 AAN meeting.

Date

The dinner will be Monday April 7th, 2025

If the event is approved by the Trustees, the proposer (Tatjana Rundek, Susan Fox-Rosellini) will manage thr event and contact current scholars, mentors, MBI leadership, ABF and AAN leadership and the Trustees to attend the dinner.

Venue

If the event is approved, the *Evelyn F. McKnight Clinical Translational Research Scholar Dinner* will be organized at a restaurant with available private room and conveniently located to the 2025 AAN meeting venue. The proposer will arrange for the venue.

Budget

We expect that 15-20 people will attend the *Evelyn F. McKnight Clinical Translational Research Scholar Dinner*. This estimate includes 4-6 Scholars, Mentorss the Trustees, and MBI leaders. We estimate a cost of \$200 per person (including beverages).

A small administrative fee may be included for the preparation and printing of the invitations (\$500). The maximum requested budget is \$4,500.